UNITY Biotechnology Revenue and Competitors

Claim your profile

Location

$290.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • UNITY Biotechnology's estimated annual revenue is currently $14.3M per year.(i)
  • UNITY Biotechnology received $55.0M in venture funding in March 2018.
  • UNITY Biotechnology's estimated revenue per employee is $233,770
  • UNITY Biotechnology's total funding is $290.6M.
  • UNITY Biotechnology's current valuation is $84.3M. (January 2022)

Employee Data

  • UNITY Biotechnology has 61 Employees.(i)
  • UNITY Biotechnology grew their employee count by -25% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com.

keywords:N/A

$290.6M

Total Funding

61

Number of Employees

$14.3M

Revenue (est)

-25%

Employee Growth %

$84.3M

Valuation

N/A

Accelerator

UNITY Biotechnology News

2022-04-20 - UNITY Biotechnology to Present Clinical Data at the Association for ...

SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company...

2022-04-20 - UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting

UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting.

2022-04-17 - UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 ...

(“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the...

2021-07-29 - Ascentage Pharma : Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, I ...

2021-07-28 - Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.7M6149%$16M
#2
$8.9M6124%N/A
#3
$8.4M6222%N/A
#4
$7.8M6268%N/A
#5
$15.1M6238%N/A

UNITY Biotechnology Funding

DateAmountRoundLead InvestorsReference
2016-10-28$116.0MBArticle
2017-08-18$35.0MBMultipleArticle
2018-03-20$55.0MCEcoR1 Capital FundArticle

UNITY Biotechnology Executives


NameTitle
Kathy WhalenExecutive Assitant to CFO and General Counsel
Lynne SullivanChief Financial Officer
Jamie DananbergChief Medical Officer
Catherine TorresExecutive Assistant To Chief Executive Officer
Mike SapiehaChief Scientific Advisor
Anirvan GhoshCEO
Susan LundeenSVP of People
Carl MillwardVice President, Translational Medicine
Nathan GuzVice President
Derek RagusaVice President, Development, Head of Product Team Leadership
Janet MartineauVice President, Head of Intellectual Property
Ben HsuVP, Clinical Development
Nathan GuzVice President of Operations